Haleon Sells Smoking Cessation Business to Dr. Reddy's Labs

Business by 2FIRSTS.ai
Jun.27.2024
Haleon Sells Smoking Cessation Business to Dr. Reddy's Labs
Haleon sells quit smoking aid business for £500 million to Dr. Reddy's Laboratories to focus on key growth areas.

According to Market Screener, on June 26th, a healthcare products and over-the-counter medication company located in Weybridge, England, Haleon, has sold its smoking cessation aid business outside of the United States to Indian pharmaceutical company Dr. Reddy's Laboratories for a maximum of £500 million (approximately $634.2 million) in order to streamline operations and focus on key growth areas.

 

The company was spun off by GlaxoSmithKline and Pfizer owns a portion of its shares. In a statement on Wednesday (26th), the department said that the funds raised from the sale will be used according to its capital allocation policy and for debt reduction.

 

Haleon owns popular brands including Sensodyne toothpaste, Aquafresh mouthwash, and over-the-counter medications Panadol and Advil. The company will receive a prepayment of 458 million pounds from the sale, with the remaining amount to be paid in installments next year and in the first half of 2026, contingent upon the achievement of specific performance targets.

 

The products for sale include nicotine replacement therapies such as patches, lozenges, and gum from brands like Nicotinell, Nicabate, Habitrol, and Thrive.

 

Haleon stated that the sale is expected to be completed in the early fourth quarter of this year. This will result in a decrease in company revenue of 0.5% and a decrease in operating profit of 1%. The company also added that all other expectations remain unchanged.

 

The company's CEO, Brian McNamara, stated:

 

Haleon Company's decision to divest its NRT business from overseas in the United States is another example of the company actively managing its asset portfolio and aligning with our strategy to implement changes to become more agile and competitive.

 

Notice

1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.

2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.

3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.

Copyright

This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.

This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.